Navigation Links
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Date:5/11/2009

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors. Mr. Lankau was most recently President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company.

"I am excited to be teaming up with such an experienced group of scientists and investors to develop clinically meaningful and novel products for inflammatory diseases," said Mr. Lankau. "Logical Therapeutics' pipeline includes important medicines for the millions of people who suffer from chronic inflammatory conditions. Logical's lead compound, LT-NS001 will be particularly important for patients whose need for non-steroidal anti-inflammatory treatment is complicated by significant gastrointestinal risks."

Mr. Lankau became President and CEO of Endo Pharmaceuticals in 2005, after having served as President and COO since 2003, and SVP of Commercial Business since 2000. Previously, Mr. Lankau was Vice President, Sales and Marketing at Alpharma, Inc. and held various management positions at Rhone-Poulenc Rorer.

"We are delighted to have Peter join the Logical team and our Board of Directors," said Lutz Giebel, Chairman of Logical Therapeutics, Inc., and the Managing Partner of SV Life Sciences Advisers LLC, a lead investor in Logical, "His experience in leading a growth oriented public company, his execution of numerous business development transactions, and his understanding of the commercially important, and value creating elements of drug development, will help propel Logical toward significant business opportunities
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the Bank of America Merrill ... in Las Vegas, NV. The formal ... AM PT/1:00 PM ET. In addition, management will be available ... An audio webcast will be available via the investor relations ...
(Date:5/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/pjbxjd/us_aco_it ... ACO IT Spending Outlook 2018" report to their ... lives covered by ACO would grow at a CAGR ... ACO IT spending has been studied on three main ... spending on services. Our research provides current market estimation ...
(Date:5/1/2015)... -- CytRx Corporation (CYTR), a biopharmaceutical research and development ... for the three months ended March 31, 2015, ... upcoming milestones for its clinical development programs. ... months of 2015, including the announcement of encouraging ... patients with soft tissue sarcoma, and positive interim ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... 2011  Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... of its European marketing authorization application ("MAA") for Pixuvri. ... the E.U. for patients with relapsed or refractory aggressive ... prior lines of therapy. CTI received the CHMP,s day ...
... 2, 2011 Shire plc (LSE: SHP, NASDAQ: ... that it has reached an agreement with the Center ... Food and Drug Administration (FDA) to conduct additional clinical ... HCl), a medicine approved in 1996 under Subpart H ...
Cached Medicine Technology:European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 2European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 3European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 4European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 5ProAmatine® (midodrine HCl) Update: Path Forward Agreed 2ProAmatine® (midodrine HCl) Update: Path Forward Agreed 3ProAmatine® (midodrine HCl) Update: Path Forward Agreed 4
(Date:5/2/2015)... 02, 2015 “ Peachtree Audio ” ... Tech Report, which features the latest and coolest technology ... and special reporter for NewsWatch, conducted the review and ... equipment. , Music is an important part of ... pampered and given the royal treatment. Peachtree Audio does ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Kare Visits LLC. ... support for busy caregivers. Kare Visits offers relief for ... assisted living facilities. According to the Caregiver Action ... an average of 20 hours a week caring for an ... the cost to hire a nurse, a caregiver is now ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... Frisco, Texas (PRWEB) May 02, 2015 ... Frisco, Texas, is proud to announce the addition of ... Jen Widerstrom is a life long athlete, growing up ... fitness passion after college by becoming a personal trainer ... since been the face of several TV shows highlighting ...
(Date:5/1/2015)... 01, 2015 Pioneer Millworks, the largest ... latest in their reclaimed wood products at the 27th ... Javits Center in NYC this May. Their newest offerings, ... much anticipated texture and color to North America's platform ... of texture and color in the design world and ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... by using genetic material ,called targeting RNA, to enter ... to stop the expression of a protein that keeps ... normal cells ,unharmed. ,The drug, developed at ... material, called In tests in mice with prostate cancer, ...
... the final day of the Eighth International Conference on ... released in which it was noted that Mercury pollution// ... everywhere from industrial sites to remote corners of the ... those threats. ,"The declaration essentially says that ...
... of twins, much in contrast with the delivery timing for ... risks if twins are delivered after 40 weeks, new research ... delivery. ,A University of Ottawa, Canada research ... was between 38 and 39 weeks. This does not compare ...
... August 13 in Nature Genetics by researchers at the ... says that there// are many more causes of mental ... large deletion in six genes on chromosome 17. The ... and other physical features that are identical to several ...
... that even in young neurons it is the survival of ... off// depends on its ability to establish connections with other ... Fred H. Gage, Ph.D., a professor in the Gene Expression ... on Age-Related Neurodegenerative Diseases. It says that a subunit of ...
... others are being sought for a joint study being ... of a// collaborative effort to better understand the genetics ... form of cancer in men. ,Cedars-Sinai Medical ... Oschin Comprehensive Cancer Institute in Los Angeles is seeking ...
Cached Medicine News:Health News:Dangers Of Mercury 2Health News:Genetics Of Mental Retardation 2Health News:Fittest Of Newborn Neurons Survive 2Health News:Fittest Of Newborn Neurons Survive 3Health News:Prostate Cancer Patients Sought for Database as Part of Joint Effort 2Health News:Prostate Cancer Patients Sought for Database as Part of Joint Effort 3
This adjustable lid speculum is angled 45 degrees and has 17 mm wire blades. It was designed to aspirate excess fluid around the eye during cataract and refractive procedures....
Angled 45 degrees. Open 13 mm blades. Screw-controlled locking mechanism. Dull finish....
Open blade design with aspiration capabilities for removing fluids from the operative site....
Solid 15 mm blades with 8 mm narrowed portion. Screw-controlled locking mechanism with stabilizing disk. Dull finish....
Medicine Products: